![The sights of Avalon Air Show 2025: Day Three [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/03/f-35-avalon-final-day-scaled-e1743079275404.jpg?#)
.jpg)
Novo gains Lexicon obesity drug; CRISPR COO to step down
Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off 57% of its workforce and Bicycle Therapeutics shook up its leadership team.
Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off 57% of its workforce and Bicycle Therapeutics shook up its leadership team.
